Innovating Health through Cutting-Edge Medical Devices and Diagnostics
We are dedicated to driving innovation and improving healthcare through advanced research and the development of breakthrough technologies.
In our state-of-the-art laboratory, we focus on the design, development and evaluation of next-generation medical devices and diagnostics. Our multidisciplinary team of scientists, engineers and healthcare experts work closely together to create solutions that improve diagnostic accuracy, facilitate medical treatments and enhance patients’ quality of life.
Our research spans a wide range of areas, from implantable devices and health monitoring systems to innovative medical imaging technologies and diagnostic tests. We strive to be at the forefront of scientific and technological advances, adopting new tools and approaches to develop solutions that meet emerging medical needs.
Our focus is on quality, accuracy and safety. We conduct rigorous studies and testing to ensure that our devices and diagnostics meet the highest quality standards and are safe for clinical use.
We work closely with pharmaceutical companies, academic institutions and healthcare professionals to bring our research from the laboratory to clinical practice. In addition, we stay abreast of industry regulations and requirements to ensure that our devices and diagnostics comply with all applicable regulations.
If you are looking for a strong and reliable collaboration in the field of medical device and diagnostics research, you’ve come to the right place. Explore our page to learn more about our projects, technologies and collaborations. We are excited to work together to drive innovation in healthcare and improve people’s lives through our advances in medical devices and diagnostics – contact us today and find out how we can make a difference together!
INTRODUCTION Tecartus is a new advanced therapy approved to treat adults with mantle cell lymphoma (MCL)¹. This disease is a lymphatic system cancer. Specifically, it
INTRODUCTION Kymriah (Novartis) is an advanced therapy medicine that belongs to the gene therapyproduct category. It is approved for B-cell acute lymphoblastic leukemia (ALL) in
INTRODUCTION ¹. CARVYKTI™ (ciltacabtagene autoleucel – Johnson & Johnson) was approved by the U.S. Food and Drug Administration (FDA) in February 2022 for the treatment
